Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay

Tyrosyl-DNA phosphodiesterase I (Tdp1) resolves topoisomerase I (Top1)-DNA adducts accumulated from natural DNA damage as well as from the action of certain anticancer drugs. Tdp1 catalyzes the hydrolysis of the phosphodiester bond between the catalytic tyrosine residue of topoisomerase I and the DNA 3′-phosphate. Only a limited number of weak inhibitors have been reported for Tdp1, and there is an unmet need to identify novel chemotypes through screening of chemical libraries. Herein, we present an easily configured, highly miniaturized, and robust Tdp1 assay using the AlphaScreen technology. Uninhibited enzyme reaction is associated with low signal, whereas inhibition leads to a gain of signal, making the present assay format especially attractive for automated large-collection high-throughput screening. We report the identification and initial characterization of four previously unreported inhibitors of Tdp1. Among them, suramin, NF449, and methyl-3,4-dephostatin are phosphotyrosine mimetics that may act as Tdp1 substrate decoys. We also report a novel biochemical assay using the SCAN1 Tdp1 mutant to study the mechanism of action of methyl-3,4-dephostatin. [Mol Cancer Ther 2009;8(1):240–8]

[1]  L. Reyno,et al.  Suramin. , 2020, Cancer practice.

[2]  Yves Pommier,et al.  Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. , 2008, Anti-cancer agents in medicinal chemistry.

[3]  Sam Michael,et al.  Compound Management for Quantitative High-Throughput Screening , 2008, JALA.

[4]  Ruili Huang,et al.  Fluorescence spectroscopic profiling of compound libraries. , 2008, Journal of medicinal chemistry.

[5]  D. Wilson.  Processing of nonconventional DNA strand break ends , 2007, Environmental and molecular mutagenesis.

[6]  Kimiyoshi Arimura,et al.  Spinocerebellar ataxia with axonal neuropathy. , 2010, Advances in experimental medicine and biology.

[7]  Yves Pommier,et al.  Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1 , 2007, Nucleic acids research.

[8]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[9]  K. Kohn,et al.  Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. , 2006, DNA repair.

[10]  Adam Yasgar,et al.  Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Yves Pommier,et al.  Inhibition of Human Tyrosyl-DNA Phosphodiesterase by Aminoglycoside Antibiotics and Ribosome Inhibitors , 2006, Molecular Pharmacology.

[12]  S. White,et al.  Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Schmalzing,et al.  The Suramin Analog 4,4′,4″,4″′-(Carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic Acid (NF110) Potently Blocks P2X3 Receptors: Subtype Selectivity Is Determined by Location of Sulfonic Acid Groups , 2006, Molecular Pharmacology.

[14]  J. Champoux,et al.  Human Tdp1 Cleaves a Broad Spectrum of Substrates, Including Phosphoamide Linkages* , 2005, Journal of Biological Chemistry.

[15]  J. Champoux,et al.  SCAN1 mutant Tdp1 accumulates the enzyme–DNA intermediate and causes camptothecin hypersensitivity , 2005, The EMBO journal.

[16]  A. Burgin,et al.  Substrate Specificity of Tyrosyl-DNA Phosphodiesterase I (Tdp1)* , 2005, Journal of Biological Chemistry.

[17]  C. Deng,et al.  Multiple Endonucleases Function to Repair Covalent Topoisomerase I Complexes in Saccharomyces cerevisiae , 2005, Genetics.

[18]  Peter J. Coassin,et al.  Piezo- and solenoid valve-based liquid dispensing for miniaturized assays. , 2005, Assay and drug development technologies.

[19]  P. Cleveland,et al.  Nanoliter dispensing for uHTS using pin tools. , 2005, Assay and drug development technologies.

[20]  J. Lupski,et al.  Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1 , 2005, Nature.

[21]  J. Lupski,et al.  Deficiency in 3′-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1) , 2005, Nucleic acids research.

[22]  Morten O. Christensen,et al.  TDP1 Overexpression in Human Cells Counteracts DNA Damage Mediated by Topoisomerases I and II* , 2004, Journal of Biological Chemistry.

[23]  James Pustejovsky,et al.  Biomedical term mapping databases , 2004, Nucleic Acids Res..

[24]  H. Spencer,et al.  Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase , 2004, Cancer Chemotherapy and Pharmacology.

[25]  Yue Yuan,et al.  Determining Appropriate Substrate Conversion for Enzymatic Assays in High-Throughput Screening , 2003, Journal of biomolecular screening.

[26]  K. Kohn,et al.  Repair of and checkpoint response to topoisomerase I-mediated DNA damage. , 2003, Mutation research.

[27]  Yves Pommier,et al.  Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. , 2003, DNA repair.

[28]  J. Champoux,et al.  Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. , 2002, Journal of molecular biology.

[29]  Chunyan Liu,et al.  Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. E. Wilson,et al.  Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Lupski,et al.  Mutation of TDP1, encoding a topoisomerase I–dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy , 2002, Nature Genetics.

[32]  L. Povirk,et al.  Conversion of Phosphoglycolate to Phosphate Termini on 3′ Overhangs of DNA Double Strand Breaks by the Human Tyrosyl-DNA Phosphodiesterase hTdp1* , 2002, The Journal of Biological Chemistry.

[33]  Y. Pommier,et al.  Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. , 2002, Nucleic acids research.

[34]  J. Champoux,et al.  The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Pouliot,et al.  Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[36]  A. Burgin,et al.  Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3'-para-nitrophenyl phosphate ester. , 2000, Nucleic Acids Research.

[37]  J. Pouliot,et al.  Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. , 1999, Science.

[38]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[39]  M. Hohenegger,et al.  Gsalpha-selective G protein antagonists. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Burgin,et al.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Charles A. Wartchow,et al.  Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. , 1996, Clinical chemistry.

[42]  K. Umezawa,et al.  Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. II. Structure determination. , 1993, The Journal of antibiotics.

[43]  K. Umezawa,et al.  Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. I. Taxonomy, isolation, and characterization. , 1993, The Journal of antibiotics.

[44]  Ricardo Macarrón,et al.  Design and Implementation of High Throughput Screening Assays , 2011, Molecular biotechnology.

[45]  A. Burgin,et al.  Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I. , 2004, Nucleic acids research.

[46]  M.,et al.  Gsa-selective G protein antagonists , 1997 .

[47]  K. Umezawa.  Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. , 1995, Advances in enzyme regulation.

[48]  S. Chatterjee,et al.  Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. , 1989, Cancer communications.

[49]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .